Company Description
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27.
It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.
In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No.
4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025.
The company was incorporated in 2010 and is based in Redwood City, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Nov 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 228 |
| CEO | Dennis Lanfear |
Contact Details
Address: 333 Twin Dolphin Drive, Suite 600 Redwood City, California 94065 United States | |
| Phone | 650 649 3530 |
| Website | coherus.com |
Stock Details
| Ticker Symbol | CHRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001512762 |
| CUSIP Number | 19249H103 |
| ISIN Number | US19249H1032 |
| Employer ID | 27-3615821 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dennis M. Lanfear | Chairman, President and Chief Executive Officer |
| Bryan J. McMichael | Chief Financial Officer |
| Jodi Sievers | Vice President of Investor Relations and Corporate Communications |
| Andy Rittenberg | Executive Vice President of General Counsel |
| Scott Saywell | Executive Vice President of Corporate Development |
| Rebecca Sunshine | Chief Human Resources Officer |
| Michael Chen | Senior Vice President of Commercial Analytics and Trade |
| Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer and Chairman of Scientific Advisory Board |
| Dr. Rosh Dias M.D., MRCP | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 3, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 15, 2025 | SC TO-I/A | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | 8-K | Current Report |